Sunesis Pharmaceuticals (NASDAQ:SNSS) has been assigned a $3.00 price objective by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 31.58% from the company’s previous close.
Several other research firms have also commented on SNSS. ValuEngine lowered Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research lowered Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Wells Fargo & Company lowered Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $2.70 to $2.00 in a research report on Tuesday. Cowen restated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Thursday, November 2nd. Finally, Oppenheimer initiated coverage on Sunesis Pharmaceuticals in a research report on Tuesday, November 21st. They issued an “outperform” rating and a $7.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company’s stock. Sunesis Pharmaceuticals has a consensus rating of “Hold” and an average target price of $3.63.
Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $2.28 on Tuesday. Sunesis Pharmaceuticals has a 52-week low of $1.82 and a 52-week high of $4.45. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of -0.34.
In other Sunesis Pharmaceuticals news, major shareholder Mpm Oncology Impact Management bought 25,300 shares of Sunesis Pharmaceuticals stock in a transaction dated Thursday, November 2nd. The stock was acquired at an average cost of $2.59 per share, with a total value of $65,527.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dayton Misfeldt bought 400,000 shares of Sunesis Pharmaceuticals stock in a transaction dated Friday, October 27th. The shares were acquired at an average cost of $2.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 506,800 shares of company stock valued at $1,091,282. Corporate insiders own 10.21% of the company’s stock.
Several hedge funds have recently made changes to their positions in SNSS. Renaissance Technologies LLC raised its stake in shares of Sunesis Pharmaceuticals by 1.1% during the 1st quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 1,230 shares during the period. Sphera Funds Management LTD. raised its stake in Sunesis Pharmaceuticals by 54.6% in the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 68,212 shares during the last quarter. Wells Fargo & Company MN raised its stake in Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 18,254 shares during the last quarter. Vanguard Group Inc. raised its stake in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after purchasing an additional 23,819 shares during the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in Sunesis Pharmaceuticals in the 2nd quarter valued at $208,000. 38.43% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Sunesis Pharmaceuticals (SNSS) Given a $3.00 Price Target by Cantor Fitzgerald Analysts” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3079498/sunesis-pharmaceuticals-snss-given-a-3-00-price-target-by-cantor-fitzgerald-analysts.html.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.